BusinessAxsome Therapeutics to Present at Upcoming Investor ConferencesBy Nasdaq OMXSep 6, 2016, 11:00 AM UTC
BusinessAxsome Therapeutics Initiates Phase 3 Study of AXS-02 for Knee Osteoarthritis Associated with Bone Marrow LesionsBy Nasdaq OMXMar 28, 2016, 11:00 AM UTC
BusinessAxsome Therapeutics Receives New U.S. Patent Covering AXS-02 for the Treatment of Complex Regional Pain SyndromeBy Nasdaq OMXMar 15, 2016, 11:00 AM UTC
BusinessAxsome Therapeutics to Present at the 2016 BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 1, 2016, 12:00 PM UTC
